Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India

European Respiratory Journal

Volumn 49, Issue 3, 2017, Pages

  Udwadia, Zarir F ^a   Ganatra, Shashank ^a   Mullerpattan, Jai B ^a  

^a P D HINDUJA NATIONAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN; BEDAQUILINE; CAPREOMYCIN; CLARITHROMYCIN; CLAVULANIC ACID; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; THIORIDAZINE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; CLINICAL ARTICLE; COHORT ANALYSIS; COMPASSIONATE USE; CONTROLLED STUDY; DRUG RESISTANT TUBERCULOSIS; FEMALE; HUMAN; INDIA; LETTER; MALE; MINIMUM INHIBITORY CONCENTRATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; YOUNG ADULT; ADOLESCENT; ISOLATION AND PURIFICATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; COMPASSIONATE USE TRIALS; DIARYLQUINOLINES; FEMALE; HUMANS; INDIA; MALE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 85030459503     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01699-2016     Document Type: Letter

References (15)

1. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307:223–227.
2. World Health Organization. Global tuberculosis report 2016. Geneva, World Health Organization, 2016.
3. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169–117.
4. Dheda K, Gumbo T, Gandhi NR, et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med 2014; 2: 321–338.
5. Udwadia ZF, Amale RA, Ajbani KK, et al. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54: 579–581.
6. Diacon AH, Pym A, Grobusch MP, et al. Multidrug resistant tuberculosis and culture conversion with bedaquiline. New Engl J Med 2014; 371: 723–732.
7. Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015; 60: 188–194.
8. Pym AS, Diacon AH, Tang SJ, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Resp J 2016; 47: 564–574.
9. Udwadia ZF, Moharil G. Multidrug-resistant-tuberculosis treatment in the Indian private sector: results from a tertiary referral private hospital in Mumbai. Lung India 2014; 31: 336.
10. World Health Organization. The use of bedaquiline to treat MDR-TB: interim policy guidance. Geneva, World Health Organization, 2013.
11. Sotgiu G, Pontali E, Migliori GB. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J 2015; 45: 25–29.
12. Bloemberg GV, Keller PM, Stucki D, et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. New Engl J Med 2015; 373: 1986–1988.
13. Wallis R. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur Respir J 2016; 48: 1526–1527.
14. Tadolini M, Lingtsang RD, Tiberi S, et al. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur Respir J 2016; 48: 1527–1529.
15. Tadolini M, Lingtsang RD, Tiberi S, et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Eur Respir J 2016; 48: 935–938.